Skip to content

AYTU BioPharma, Inc. Common Stock (AYTU) — WACC Analysis

WACC Breakdown

AYTU BioPharma, Inc. Common Stock (AYTU) has a weighted average cost of capital (WACC) of 12.4%. The cost of equity is 8.9%, derived from a beta of 1.00 and a risk-free rate of 4.7%. The after-tax cost of debt is 19.7%. The capital structure is 67.8% equity and 32.2% debt.

Interpretation

A WACC of 12.4% indicates that the market perceives AYTU BioPharma, Inc. Common Stock as higher-risk, requiring a greater return to compensate investors.

Investors can compare AYTU's WACC of 12.4% against industry peers to gauge its relative financing costs. A beta of 1.00 reflects the stock's volatility relative to the broader market.

DeepViews
VALUATION

AYTU WACC: 12.36% for AYTU BioPharma, Inc. Common Stock

Current inputs imply a 8.90% cost of equity and a 19.66% pre-tax cost of debt. Use this discount rate as a starting point for DCF validation.

[01]Current Market Data
Loading market data...
[02]
WACC Calculation Process
1
Market Data Loaded
2
Company Data Fetched
3
Beta Calculated (5Y)
4
Inputs Auto-Populated
5
WACC Calculated
[03]
Step 2: Enter Ticker Symbol
Quick search:
Step 4: Review Auto-Populated WACC Inputs

Values are automatically populated from real data. You can adjust them manually if needed.

4.30%
1.000
4.23%
5.00%
21.00%
70.00%
Debt: 30.00%Equity: 70.00%

Please enter a valid company ticker to calculate WACC

AYTU BioPharma, Inc. Common Stock Common Stock (AYTU) WACC Results
Weighted Average Cost of Capital
12.36%
Cost of Equity
8.90%
Risk-Free Rate4.67%
Beta1.00
Market Risk Premium4.23%
Cost of Debt
19.66%
Pre-Tax Cost of Debt19.66%
Tax Rate0.00%
Tax Shield0.00%
Capital Structure
Equity: 67.82%($24.04M)
Debt: 32.18%($11.41M)
Equity Component
6.04%
67.82% × 8.90%
Debt Component
6.32%
32.18% × 19.66%

AYTU BioPharma, Inc. Common Stock (AYTU) WACC in context

AYTU BioPharma, Inc. Common Stock (AYTU) currently screens with an estimated WACC of 12.36%. That blends a 8.90% cost of equity, a 19.66% pre-tax cost of debt, and a 67.82% equity weight into the discount rate you would typically use in a DCF model.

screens as a relatively high discount rate, which makes valuation more sensitive to execution and capital structure risk.

What AYTU WACC implies

A 12.36% discount rate screens as a relatively high discount rate, which makes valuation more sensitive to execution and capital structure risk.

How this page calculates AYTU

This page combines CAPM-based cost of equity with SEC-derived debt and capital structure inputs. The current beta is 1.00 and equity accounts for 67.82% of capital.

What to do next

Validate business quality on the company page, then carry the same discount-rate assumptions into the DCF page to test fair value sensitivity.

Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.

AYTU WACC: 12.36% — AYTU BioPharma, Inc. Common Stock Cost of Capital (August 2026) | DeepViews